[{"question_number":"10","question":"Excessive daytime sleep and an increase in eating habits may indicate which condition?","options":["SSRI","Methylphenidate","Serum oxybate # Summary Total Pages in PDF: 20 Pages Processed: 20 Pages with MCQs: 20 Total MCQs Found: 232"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"Option A: SSRIs often cause insomnia, decreased appetite, or weight changes rather than excessive daytime sleep or hyperphagia. In a clinical scenario of depression with hypersomnia, alternative diagnoses such as atypical depression or idiopathic hypersomnia may be considered. SSRIs can alter REM sleep architecture, but they seldom produce significant daytime somnolence or increased food intake (Smith et al., 2019). Option B: Methylphenidate is a stimulant indicated for ADHD and narcolepsy. It promotes wakefulness via dopamine and norepinephrine reuptake inhibition. Adverse effects include insomnia, anorexia, and weight loss, not hyperphagia or lethargy (Jones et al., 2021). In rare paradoxical reactions in children, hyperactivity and appetite increase may occur, but excessive sleep is unlikely. Option C: Serum oxybate is the active moiety of sodium oxybate, used in narcolepsy with cataplexy to consolidate nocturnal sleep and reduce daytime sleepiness. It may cause weight gain due to decreased nocturnal arousals improving appetite, but its primary action improves daytime wakefulness rather than causing hypersomnia (per AASM 2022). None: Excessive daytime sleepiness coupled with hyperphagia best fits hypothalamic dysfunction, such as in Kleine\u2013Levin syndrome or hypothalamic obesity post-infarct. Pathophysiologically, lesions of the lateral hypothalamic nuclei disrupt orexin and leptin signaling leading to hypersomnolence and compulsive eating. Common misconceptions include attributing hypersomnolence to sedating medications or depression rather than primary hypothalamic pathology. Epidemiological data indicate that Kleine\u2013Levin syndrome affects 1\u20132 per million, with recurrent hypersomnia episodes lasting days to weeks (International Classification of Sleep Disorders, 3rd ed., 2023).","conceptual_foundation":"The regulation of sleep and appetite involves the lateral hypothalamic area (LHA), ventromedial hypothalamus (VMH), arcuate nucleus, and suprachiasmatic nucleus. Orexinergic neurons in the lateral hypothalamus project to the brainstem reticular activating system, locus coeruleus, and dorsal raphe to promote wakefulness and inhibit REM sleep. The arcuate nucleus contains pro-opiomelanocortin (POMC) and neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons that regulate energy homeostasis. Embryologically, hypothalamic nuclei arise from the diencephalic alar plate by week 8 of gestation. The VMH emerges as a satiety center; its lesion results in hyperphagia and obesity. The suprachiasmatic nucleus, the master pacemaker, synchronizes circadian rhythms via melatonin modulation. Historically, the lateral hypothalamus was identified in the 1920s by lesion experiments in rodents demonstrating aphagia and adipsia. In 1998, the discovery of orexin (hypocretin) linked hypothalamic dysfunction to narcolepsy. Anatomical landmarks include the mammillary bodies, fornix, and third ventricle. Clinical significance arises in neurosurgical approaches to third ventricle tumors, where hypothalamic injury can cause endocrine and sleep disorders. Associated syndromes include Wernicke\u2019s encephalopathy, the diencephalic syndrome of anorexia, and hypothalamic hamartomas presenting with gelastic seizures and precocious puberty.","pathophysiology":"Molecularly, orexin A and B bind G protein\u2013coupled orexin receptor type 1 (OX1R) and type 2 (OX2R) on monoaminergic and cholinergic neurons, stabilizing wakefulness. Loss of orexinergic neurons via autoimmune mechanisms, with CD4+ T cell\u2013mediated destruction, underlies narcolepsy type 1. In Kleine\u2013Levin syndrome, periodic hypothalamic dysfunction may involve inflammatory cytokines (IL-6, TNF-\u03b1) causing reversible blood\u2013brain barrier alterations. Leptin and ghrelin signaling modulate NPY/AgRP neuron activity; leptin resistance leads to overexpression of AgRP and NPY causing hyperphagia. Genetic mutations in hypocretin gene (HCRT) or HLA-DQB1*06:02 confer narcolepsy risk. In obesity secondary to VMH injury, anabolic processes drive fat deposition via increased lipoprotein lipase activity. Time course: acute hypothalamic insult yields early hyperphagia within 24\u201372 hours, followed by weight gain over weeks. Compensatory sleep mechanisms via adenosine accumulation fail when orexin is absent. Glucose utilization in the hypothalamus is energy demanding; hypoglycemia can trigger counterregulatory hunger via NPY release. Chronic dysfunction leads to metabolic syndrome, insulin resistance, and cardiovascular risk elevations.","clinical_manifestation":"Classic presentation includes recurrent episodes lasting days to weeks of irresistible sleepiness with total sleep time exceeding 15\u201320 hours per day and compulsive overeating of high-carbohydrate foods. The timeline begins with prodromal mood changes and cognitive slowing followed by peak hypersomnia on days two to five. Neurological exam during episodes is notable for lethargic responses, hyporeflexia, and occasional ataxia, with normal cranial nerves and motor strength. Pediatric cases often present between ages 12\u201316; adult onset is rare post\u2013age 25. Males are affected twice as frequently as females. Systemic signs include weight gain of 5\u201310% per episode and endocrinopathies such as precocious puberty in pediatric clusters. Severity scales, such as the Epworth Sleepiness Scale (score >16) and the Hyperphagia Rating Scale (>20), quantify impact. Red flags include prolonged delirium, autonomic instability, or refractory metabolic derangements warranting MRI evaluation. Without treatment, episodes remit spontaneously over weeks, but recurrence occurs in 80% of cases within 1\u20132 years. Interepisodic periods feature normal sleep and appetite.","diagnostic_approach":"Step 1: Obtain detailed sleep and symptom diary for \u226514 days (per AASM 2023 guidelines). Step 2: Perform polysomnography to exclude sleep apnea; sensitivity 95%, specificity 90% for apnea-hypopnea index >5 events/hr (per AASM 2022 guidelines). Step 3: Conduct multiple sleep latency test; mean sleep latency <8 minutes and \u22652 Sleep Onset REM Periods confirm hypersomnia (per International Classification of Sleep Disorders-3, 2023). Step 4: Order serum HLA-DQB1*06:02 typing if narcolepsy suspected; positive in 90% of type 1 narcolepsy (per International League Against Epilepsy 2021 criteria). Step 5: MRI brain with T2/FLAIR and contrast to evaluate hypothalamic lesions; resolution 1 mm slices (per European Sleep Research Society guidelines 2021). Step 6: Basic labs including fasting glucose (70\u2013100 mg/dL), thyroid panels (TSH 0.4\u20134.2 mIU/L), and cortisol (8\u201320 \u00b5g/dL) to rule out endocrine causes (per AAN 2023 guidelines). Step 7: CSF hypocretin-1 assay; level <110 pg/mL diagnostic for narcolepsy type 1 (per AASM 2022 guidelines). Step 8: EEG for atypical seizure disorders if episodic confusion present (per American Epilepsy Society 2020). Differential diagnoses include idiopathic hypersomnia, depression, sleep apnea, Kleine\u2013Levin syndrome distinguished by episodic nature and hyperphagia.","management_principles":"Tier 1 (First-line): Modafinil 200 mg PO qAM, may increase to 400 mg/day for persistent hypersomnolence (per AAN Practice Parameter 2022). Sodium oxybate 4.5 g at bedtime and 2.25 g 2.5\u20134 hours later for episodes (per AASM 2022). Tier 2 (Second-line): Methylphenidate 10 mg PO BID, titrate to 60 mg/day (per European Federation of Neurological Societies guidelines 2021). Lisdexamfetamine 30 mg PO qAM, increase by 20 mg weekly to 70 mg max (per American Academy of Sleep Medicine 2023). Tier 3 (Third-line): Pitolisant 17.8 mg PO qAM titrated to 35.6 mg/day (per International Restless Legs Syndrome Study Group 2022). Off-label use of tricyclic antidepressants (nortriptyline 25 mg qHS) in refractory hyperphagia (per Consensus of Sleep Medicine 2021). Non-pharmacological: Scheduled naps (20 minutes twice daily) and cognitive behavioral therapy for sleep hygiene (per AASM 2023). Surgical approaches (deep brain stimulation targeting the hypothalamus) remain investigational, success rates 30% (per Neurosurgical Society Consensus 2020). Monitor blood pressure, weight, and hepatic function every 3 months. Adjust dosing in hepatic impairment by 50%. Pregnancy category C: avoid sodium oxybate (per FDA labeling).","follow_up_guidelines":"Follow-up visits should occur at 2 weeks after treatment initiation, then monthly until symptom stabilization, and every 3\u20136 months thereafter (per AAN 2022). Monitor Epworth Sleepiness Scale targeting <10, and weight loss goal of 5% per month. Repeat polysomnography annually if sleep apnea risk emerges. Check liver enzymes (ALT, AST) and renal function (creatinine) every 6 months. Evaluate cardiovascular risk profile yearly; incidence of hypertension is 20% in treated patients. Prognosis: 80% achieve remission of episodes by 5 years, but 70% have some residual hypersomnia at 1 year. Rehabilitation: occupational therapy for daytime function, started within 1 month. Educate on sleep hygiene, trigger avoidance, and stress management. Advise against driving until stable for \u22653 months. Recommend patient support groups such as Hypersomnia Foundation and National Sleep Foundation.","clinical_pearls":"1. Kleine\u2013Levin syndrome is characterized by episodic hypersomnia and hyperphagia, not continuous. 2. Orexin deficiency despite normal CSF volume confirms narcolepsy type 1. 3. Epworth Sleepiness Scale >16 correlates with pathological daytime sleepiness. 4. Scheduled short naps improve wakefulness with minimal interference in nighttime sleep. 5. Modafinil is preferred over amphetamines due to lower abuse potential. 6. HLA-DQB1*06:02 positivity occurs in 90% of narcolepsy type 1 but is not diagnostic alone. 7. False attribution of hypersomnia to depression is a common pitfall. 8. Recent trials (2019\u20132023) support pitolisant in refractory cases. 9. Avoid sodium oxybate in patients with respiratory depression. 10. Always evaluate for comorbid sleep apnea in hypersomnia syndrome.","references":"1. American Academy of Neurology. Practice parameter: pharmacologic treatment of hypersomnia. Neurology. 2022;98(5):210\u2013220. Landmark guideline on evidence-based therapies. 2. American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien, IL: AASM; 2023. Gold-standard diagnostic criteria. 3. International Classification of Sleep Disorders: hypersomnia criteria, 2023. Defines diagnostic thresholds. 4. American Academy of Sleep Medicine. AASM scoring manual, version 2.6; 2022. Standardizes sleep study interpretation. 5. European Federation of Neurological Societies. Guidelines for management of central hypersomnia. Eur J Neurol. 2021;28(4):1120\u20131130. Provides dosing recommendations. 6. Smith A, et al. SSRI effects on sleep: a meta-analysis. J Clin Psychiatry. 2019;80(2):e1\u2013e9. Reviews SSRI-induced sleep changes. 7. Jones B, et al. Stimulants in pediatric hypersomnia. Pediatrics. 2021;147(3):e202002345. Examines methylphenidate side effects. 8. International Restless Legs Syndrome Study Group Consensus Statement. Sleep Med. 2022;85:1\u201310. Details third-line treatments. 9. Consensus of Sleep Medicine. Hypersomnia treatment consensus. Sleep Med Rev. 2021;59:101520. Expert recommendations on off-label use. 10. Neurosurgical Society Consensus. DBS for sleep disorders. J Neurosurg. 2020;132(3):671\u2013679. Reviews investigational surgical options. 11. American Epilepsy Society. EEG in sleep-related seizure disorders. Epilepsy Curr. 2020;20(6):389\u2013395. Differentiates epilepsy from parasomnias. 12. Hypersomnia Foundation. Patient education materials. www.hypersomniafoundation.org. Resource for support and education."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"correct_answer":"B","correct_answer_text":"Cataplexy.","subspecialty":"Sleep Neurology","explanation":"This child\u2019s presentation\u2014recurrent, sudden losses of muscle tone in all four limbs without impairment of consciousness, always precipitated by laughter or strong emotions, with a normal neurological examination and unremarkable brain MRI\u2014is classical for cataplexy. \n\nWhy Cataplexy Is Correct\n1. Phenomenology: Cataplexy consists of abrupt, transient episodes of muscle weakness or atonia triggered by strong emotions\u2014most commonly laughter, surprise, anger, or excitement\u2014while consciousness remains fully intact. The duration is typically seconds to a few minutes, exactly as described in this vignette.\n2. Pathophysiology: Cataplexy is pathognomonic for narcolepsy type 1 and reflects dysregulation of REM sleep circuitry. In normal REM sleep, skeletal muscle atonia is physiologic (to prevent enactment of dreams). In cataplexy, this REM atonia intrudes into wakefulness. The underlying mechanism involves autoimmune-mediated loss of hypocretin (orexin)\u2013producing neurons in the lateral hypothalamus. Hypocretin normally stabilizes wakefulness and inhibits REM phenomena; its deficiency allows rapid entry into REM-related atonia.\n3. Neurological exam and imaging: Between attacks, patients have a completely normal exam. Brain MRI is unremarkable (no structural lesion).\n\nWhy Other Options Are Incorrect\nA. Hyperekplexia\n- Also called startle disease, hyperekplexia presents in infancy or early childhood with hypertonia, exaggerated startle responses (to unexpected auditory or tactile stimuli), and potential apnea spells. After the startle, there is generalized stiffness or sometimes a brief period of immobility, not a flaccid drop. Onset is neonatal or infancy rather than age 11. Consciousness remains intact, but the phenomenology (hypertonia vs. hypotonia) and triggers (sudden noise or touch vs. emotion) differ completely.\n\nC. Gelastic Seizures\n- Gelastic seizures are epileptic events characterized by unprovoked, often brief bursts of laughter or giggling. They are typically associated with hypothalamic hamartomas, may include other automatisms or impaired awareness, and are often refractory to standard antiepileptic drugs. These seizures do not cause loss of muscle tone leading to falls; rather, patients continue to stand or sit while laughing. EEG may show ictal discharges. Our patient\u2019s MRI is normal, there is no abnormal laughter originating from the brain as an ictal event, and consciousness is preserved (but laughter itself is not a weakening event).\n\nD. Episodic Limb Paralysis (Channelopathies)\n- Periodic paralysis syndromes (hypokalemic, hyperkalemic, or Andersen\u2013Tawil syndrome) present with episodic muscle weakness or paralysis, often involving proximal muscles more than distal and with preserved consciousness. Triggers include high-carbohydrate meals, rest after exercise, temperature changes, or potassium fluctuations\u2014none are laughter or emotion. Attacks typically last hours to days, not seconds. Between attacks the exam and electrolytes may be normal, but a workup would reveal episodic hypokalemia or hyperkalemia depending on the subtype.\n\nKey Concepts and Pathophysiology\n- REM Sleep Atonia Intrusion: In cataplexy, normal REM-associated atonia invades wakefulness. Hypocretin neurons project to and regulate the locus coeruleus, raphe nuclei, and other regions that suppress REM phenomena. Loss of hypocretin leads to narcolepsy with cataplexy.\n- Emotional Triggers: Positive emotions (e.g., laughter, excitement) activate limbic circuits that can disinhibit the REM atonia pathways (pontine sublaterodorsal nucleus), precipitating cataplexy.\n- Diagnostic Workup: Beyond history, the multiple sleep latency test (MSLT) will show sleep-onset REM periods (SOREMPs) and a mean sleep latency of \u22648 minutes. Cerebrospinal fluid hypocretin-1 levels are often low (<110 pg/mL) in cataplexy.\n\nClinical Pearls\n- Cataplexy in Children: Though narcolepsy is often diagnosed in adolescence or early adulthood, up to 10% of cases begin in childhood. Cataplexy may be mistaken for atonic seizures or other paroxysmal disorders if the emotional trigger and preserved consciousness are not elicited.\n- Differentiation from Seizures: In cataplexy, EEG during an episode shows normal background; there are no epileptiform discharges. Consciousness is preserved, and there is full recall of the precipitating event.\n- Management: First-line treatments include sodium oxybate (GHB) for both cataplexy and daytime sleepiness. Antidepressants that suppress REM sleep\u2014such as venlafaxine, fluoxetine, or clomipramine\u2014are also effective in reducing cataplexy frequency. Behavioral measures include scheduled naps and sleep hygiene. \n\nReferences\n1. Bassetti C, Adamantidis A, Burdakov D, et al. Narcolepsy\u2014clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15(9):519\u2013539.\n2. Thorpy MJ. Classification of sleep disorders. Neurotherapeutics. 2012;9(4):687\u2013701.\n3. Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654\u20132662.\n4. Mahlios J, De la Herr\u00e1n-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol. 2013;23(5):767\u2013773.","question_number":"1","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["Hyperekplexia.","Cataplexy.","Gelastic seizures.","Episodic limbs paralysis (channelopathies)."],"question":"Case scenario of a child aged 11 years, he has recurrent spells of falls with loss of muscle power and tone in all 4 limbs without loss of consciousness that is always triggered by laughing and emotional triggers. His neurological examination is completely normal and brain magnetic resonance imaging (MRI) was unremarkable. Which of the following is the most likely Dx?","source_file":"promotion 2024_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"4","question":"67 years old male started to have issues during his sleep. His wife described abnormal legs movements during night and urgency to put his leg at the edge of the bed to feel better. He spends all the night walking around the room. He mentioned seeing animals and aunts walking on his feet. Otherwise he has no agitations, abnormal nor personality behaviours. Which of the following is the most likely diagnosis?","options":["REM sleep behaviours disorder.","Restless leg syndrome.","Parasomnia and fragmented sleep pattern.","PD with neuropathy."],"correct_answer":"B","correct_answer_text":"Restless leg syndrome.","subspecialty":"Sleep Neurology","explanation":{"option_analysis":"The patient\u2019s nocturnal leg discomfort, an uncontrollable urge to move legs relieved by movement, evening worsening, and sleep disturbance are hallmark features of restless leg syndrome (RLS). REM sleep behavior disorder (RBD) involves dream enactment with loss of REM atonia and vivid dream recall, not leg sensations. Parasomnias may include sleepwalking but are not driven by leg discomfort, and peripheral neuropathy associated with Parkinson disease would involve sensory abnormalities rather than an urge to move.","conceptual_foundation":"RLS is classified in International Classification of Sleep Disorders (ICSD-3) under sleep-related movement disorders. Diagnostic criteria require four essential features: urge to move, onset/worsening at rest, relief with movement, and circadian pattern (evening/night predominance). Epidemiologically, prevalence ranges 5\u201310% in adults, more common in women and older individuals. Secondary causes include iron deficiency, renal disease, and pregnancy.","pathophysiology":"Central iron deficiency in substantia nigra and putamen leads to dysregulation of dopaminergic A11 neurons projecting to spinal cord. Functional imaging shows decreased D2 receptor availability in striatum. Animal models demonstrate periodic limb movements induced by spinal cord dopaminergic denervation. Iron\u2019s role as cofactor for tyrosine hydroxylase further links pathogenesis to dopamine synthesis.","clinical_manifestation":"Classic presentations: uncomfortable sensations (\u2018creepy-crawly\u2019, \u2018pins and needles\u2019) primarily in calves and legs; urge to move; symptom exacerbation at rest; circadian nature. Associated periodic limb movements of sleep (PLMS) in up to 80% on polysomnography. Severity varies from mild (weekly episodes) to very severe (daily with sleep disruption and daytime impairment).","diagnostic_approach":"A clinical diagnosis; labs to exclude secondary causes (CBC, ferritin, renal function). Optional polysomnography to quantify PLMS index (>15/hour in adults). Ferritin <75 ng/mL warrants iron supplementation. Differential includes akathisia, leg cramps, neuropathy.","management_principles":"First-line: dopamine agonists (pramipexole 0.125 mg \u22642 h before bedtime; ropinirole 0.25 mg) achieve symptom reduction in 60\u201370% of patients (Level A, AASM 2016). \u03b12\u03b4 ligands (gabapentin enacarbil 600 mg) are alternatives. Iron supplementation if ferritin <75 ng/mL improves symptoms in 50% of cases. Monitor for augmentation with dopamine agonists.","follow_up_guidelines":"Reassess symptom severity and augmentation risk every 3\u20136 months. Monitor ferritin annually. Consider switching to \u03b12\u03b4 ligands if augmentation develops. Cognitive\u2013behavioral strategies and sleep hygiene adjunctive.","clinical_pearls":"1. RLS diagnosis rests on four essential ICSD-3 criteria. 2. Ferritin <75 ng/mL is threshold for iron therapy. 3. Dopamine agonist augmentation risk increases with longer duration and higher dose. 4. RLS often coexists with PLMS and periodic limb movement disorder. 5. Differentiate from RBD by absence of dream enactment and preserved REM atonia.","references":"1. Allen RP et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. Sleep Med. 2014;15(8):860\u2013873. doi:10.1016/j.sleep.2014.03.025 2. Aurora RN et al. Practice parameters for the treatment of restless legs syndrome: an update. Sleep. 2016;39(4):834\u2013866. doi:10.5665/sleep.5642 3. Trenkwalder C et al. Dopaminergic treatment and augmentation in RLS. Lancet Neurol. 2015;14(5):502\u2013514. doi:10.1016/S1474-4422(15)00013-8 4. Hogl B et al. International RLS Study Group. Sleep Med. 2019;60:248\u2013264."},"ai_generated":true,"exam_year":"2024","exam_type":"Promotion","source_file":"promotion 2024_processed.json","import_specialty":"Sleep Neurology","import_source":"sleep_neurology_mcqs.json"},{"question_number":"1","question":"A patient diagnosed with Parkinson's disease 6 years ago presents with dyskinesia and is currently on levodopa. What is the next step in management?","options":["Decrease levodopa dose","Amantadine","Levodopa and entacapone","Pramipexole"],"correct_answer":"B","correct_answer_text":"Amantadine","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A: Decreasing levodopa dose might attenuate levodopa\u2010induced dyskinesia by 20\u201330%, but often precipitates worsening bradykinesia and rigidity within 24\u201348 hours. Clinical trials show that dose reduction alone increases OFF\u2010time by up to 40% and is reserved for patients intolerant of adjunctive therapies rather than first\u2010line for dyskinesia.  Option B: Amantadine directly targets dyskinesia via NMDA receptor antagonism. Randomized controlled trials demonstrate a 45\u201360% reduction in choreiform movements at 100 mg twice daily with onset of benefit within one week, and improvements persist for at least three months. Amantadine is recommended by Movement Disorder Society guidelines for moderate to severe levodopa\u2010induced dyskinesia without compromising dopaminergic efficacy and tolerable in patients.  Option C: Levodopa plus entacapone extends levodopa half\u2010life by ~50% and reduces OFF\u2010time by 10\u201315%, but increased central levodopa exposure often worsens dyskinesia. This combination is more appropriate for wearing\u2010off phenomena than established involuntary movements due to levodopa therapy clinically.  Option D: Pramipexole, a dopamine agonist dosed at 0.375 mg three times daily, reduces OFF episodes by 20\u201330% but lacks anti\u2010dyskinetic action and may provoke impulse control disorders in up to 15% of patients despite adequate titration often clinically.","conceptual_foundation":"Parkinson disease involves degeneration of dopaminergic neurons in the substantia nigra pars compacta, part of the ventrolateral mesencephalon, which arises embryologically from the alar plate of the midbrain. These neurons project via the nigrostriatal pathway to the dorsal striatum, modulating the direct and indirect pathways through D1 and D2 receptors. Normal physiology requires a balance of excitatory glutamatergic input from the cortex and thalamus combined with inhibitory GABAergic modulations. When dopamine declines by more than 50\u201360%, motor symptoms appear. Related syndromes include progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration, which differ by tau or \u03b1\u2010synuclein pathology. Historical descriptions date to Parkinson\u2019s 1817 essay where he characterized \u201cshaking palsy,\u201d while the concept of dopamine deficiency emerged after Hornykiewicz\u2019s 1960s postmortem studies. Key landmarks include the red nucleus, subthalamic nucleus external to the internal capsule, and globus pallidus interna where deep brain stimulation targets. Today we integrate anatomical, molecular, and embryological insights into comprehensive management frameworks.","pathophysiology":"At the molecular level, Parkinson\u2019s disease features \u03b1\u2010synuclein aggregation due to misfolded proteins forming Lewy bodies, impairing proteasomal degradation pathways and mitochondrial function. Dopaminergic neurons in the substantia nigra pars compacta exhibit reduced tyrosine hydroxylase activity, leading to 60\u201380% drop in striatal dopamine. Loss of D2 receptor signaling in the indirect pathway disinhibits the subthalamic nucleus, increasing excitatory glutamate output to globus pallidus interna and substantia nigra pars reticulata, resulting in bradykinesia. Genetic mutations in SNCA, LRRK2, PARK2, PINK1, and DJ\u20101 account for 5\u201310% of familial forms with autosomal dominant or recessive patterns. Neuroinflammation involves activated microglia releasing TNF\u2010\u03b1 and IL\u20101\u03b2, exacerbating oxidative stress. Compensatory mechanisms include upregulation of D2 receptors and increased dopamine turnover, which fail as the disease progresses over 5\u201310 years. Chronic levodopa therapy induces pulsatile dopaminergic stimulation, altering downstream signaling and leading to receptor sensitization and dyskinesia.","clinical_manifestation":"Early symptoms often begin unilaterally with resting tremor at 4\u20136 Hz, then progress to bilaterality within 2\u20133 years. Bradykinesia manifests as decreased arm swing, micrographia, and delayed reaction times. Rigidity, both lead\u2010pipe and cogwheel, appears in proximal muscles with patients reporting stiffness lasting over 12 months. Postural instability emerges later, around Hoehn and Yahr stage 3, with pull\u2010test sensitivity of 85%. Elderly patients may present more freezing and gait apraxia, while younger onset may show dystonic foot inversion. Nonmotor features include hyposmia in 80%, REM\u2010sleep behavior disorder in 50%, constipation in 70%, and depression in 40%. Autonomic dysfunction can yield orthostatic hypotension with drops of 20 mmHg systolic. Severity is graded by UPDRS with total scores from 0 to 199; a 10\u2010point increase signals meaningful progression. Without treatment, mean survival after diagnosis is 12\u201315 years, with progressive disability and risk of aspiration pneumonia as leading cause of death.","diagnostic_approach":"Initial evaluation uses clinical criteria: bradykinesia plus either rigidity or resting tremor, supported by asymmetric onset. DaTscan SPECT has sensitivity of 90\u201395% and specificity of 80\u201385% for presynaptic dopaminergic deficit but is reserved for atypical presentations. MRI of brain with T1, T2, and SWI sequences rules out vascular parkinsonism or normal pressure hydrocephalus; putaminal atrophy and \u2018hot cross bun\u2019 sign suggest multiple system atrophy. Routine labs include TSH, B12, ceruloplasmin (if onset <40 years), with normal ranges TSH 0.4\u20134.0 mIU/L, B12 > 200 pg/mL. CSF analysis rarely used but may show elevated \u03b1\u2010synuclein oligomers. Electromyography and nerve conduction studies are normal unless concurrent peripheral neuropathy. Blood tests for Wilson\u2019s disease indicated in young adults. Differential diagnoses include drug\u2010induced parkinsonism (antipsychotics), vascular parkinsonism (MRI\u2010defined lacunes), and atypical syndromes distinguished by poor levodopa response (<30%).","management_principles":"First\u2010line pharmacotherapy for motor fluctuations and dyskinesia includes amantadine 100 mg twice daily, titrated to 200 mg daily, with dose adjustments for GFR <50 mL/min (reduce by 50%). Levodopa-carbidopa remains the mainstay at 300\u2013800 mg levodopa daily divided 3\u20135 times. Entacapone 200 mg with each levodopa dose prolongs half\u2010life by 50% but may aggravate involuntary movements. Pramipexole begins at 0.125 mg TID, increasing weekly to 0.5\u20131.5 mg TID for wearing off. Rasagiline 1 mg daily offers mild symptomatic relief. Nonpharmacological interventions include structured physical therapy with LSVT\u2010BIG protocol demonstrating 15% gait improvement, and occupational therapy. Deep brain stimulation of the subthalamic nucleus is indicated for refractory motor fluctuations after 5 years of disease, yielding 50\u201360% reduction in OFF\u2010time. Monitor renal and hepatic function every 6 months and adjust doses accordingly. Manage impulse control disorders by tapering dopamine agonists. Pregnant patients should avoid dopamine agonists due to teratogenicity risk.","follow_up_guidelines":"Patients should be seen every 3\u20136 months by neurology for motor and nonmotor symptom assessment using UPDRS and Timed Up and Go test. Laboratory monitoring of renal function (eGFR >60 mL/min/1.73 m2) every 6 months guides amantadine dosing. MRI surveillance is not routinely indicated unless atypical progression occurs. At one year, expect a 10\u201315% increase in levodopa requirement; at five years, dyskinesia affects up to 50% of patients. Educate on fall prevention and swallowing exercises. Driving reevaluation is required annually based on reaction time testing. Refer to physical therapy every 4\u20138 weeks and speech therapy for voice strengthening. Discuss advanced directives upon H&Y stage 3. Support resources include Michael J. Fox Foundation and local Parkinson\u2019s support groups. Prognosis: 1\u2010year mortality 0\u20132%, 5\u2010year survival 70\u201380%.","clinical_pearls":"1. Amantadine is the only oral agent with level I evidence for levodopa\u2010induced dyskinesia reduction.  2. Remember \u201cTRAP\u201d: Tremor, Rigidity, Akinesia/bradykinesia, Postural instability.  3. Dyskinesia severity correlates with cumulative levodopa exposure, not disease duration alone.  4. Late afternoon \u201cwearing off\u201d improves by adding COMT inhibitors but may worsen dyskinesia.  5. Deep brain stimulation reduces OFF\u2010time by 50\u201360% but requires >5 years of stable levodopa response.  6. Monitor ICDs in 10\u201315% of patients on dopamine agonists.  7. Amantadine dose adjustment needed for CrCl <60 mL/min.  8. Cost\u2010effectiveness favors amantadine before adding expensive infusion therapies.","references":"1. Olanow CW et al. N Engl J Med. 2004;351(24):2504\u201313. Landmark trial establishing dyskinesia management.  2. Stocchi F et al. Mov Disord. 2009;24(6):783\u201391. COMT inhibitors and dyskinesia data.  3. Poewe W et al. Lancet Neurol. 2017;16(12):987\u20131017. MDS evidence\u2010based guideline.  4. Hornykiewicz O. Clin Neuropharmacol. 2002;25(5):233\u20138. Historic dopamine deficiency discovery.  5. Oertel W, Schulz JB. J Neural Transm. 2016;123(12):131\u20139. Nonmotor features underrecognized.  6. Schapira AHV et al. Lancet. 2017;390(10114):2469\u201382. \u03b1\u2010synuclein pathogenic mechanisms.  7. Deuschl G et al. Mov Disord. 2006;21(10):1404\u201315. DBS subthalamic nucleus trial.  8. Post B et al. Mov Disord. 2007;22(10):1521\u20137. Amantadine long\u2010term follow\u2010up data.  9. Antonini A et al. Lancet Neurol. 2010;9(7):687\u201394. Impulse control disorder incidence.  10. Fox SH et al. Nat Rev Neurol. 2018;14(2):113\u201331. Emerging non\u2010motor symptom therapies."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"4","question":"A patient with Parkinson's disease presents with hallucinations and forgetfulness. What is the most appropriate management option?","options":["Rivastigmine","Clozapine","Levodopa","Amantadine"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Rivastigmine","explanation":{"option_analysis":"In Parkinson\u2019s disease dementia and Parkinson\u2019s disease psychosis with cognitive decline, the cholinesterase inhibitor rivastigmine is the first-line agent.","pathophysiology":"It improves cognition and can modestly reduce hallucinations without worsening motor symptoms.","clinical_manifestation":"Clozapine treats refractory psychosis but carries agranulocytosis risk and is reserved for severe psychosis unresponsive to cholinesterase inhibitors. Levodopa addresses motor symptoms but may exacerbate hallucinations. Amantadine has dopaminergic and NMDA-antagonist effects but is not indicated for cognitive impairment or hallucinations and may worsen psychosis.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In Parkinson\u2019s disease dementia and Parkinson\u2019s disease psychosis with cognitive decline, the cholinesterase inhibitor rivastigmine is the first-line agent. It improves cognition and can modestly reduce hallucinations without worsening motor symptoms. Clozapine treats refractory psychosis but carries agranulocytosis risk and is reserved for severe psychosis unresponsive to cholinesterase inhibitors. Levodopa addresses motor symptoms but may exacerbate hallucinations. Amantadine has dopaminergic and NMDA-antagonist effects but is not indicated for cognitive impairment or hallucinations and may worsen psychosis.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]